LETTER TO PROVIDERS
May 24, 2002
Dear Prescribing Practitioners and Pharmacy Providers:
In January 2002 you were notified that the Department of Health and Hospitals (DHH)
planned to establish a pharmacy prior authorization (PA) process with a
preferred drug list (PDL) for certain drugs covered under the Medicaid Pharmacy
Benefits Program. Workshops on the new prior authorization process
were held in February and March. On
May 22, 2002 the Louisiana Legislature"s Joint Committee on Health and Welfare
approved the Department to implement this process effective
June 10, 2002.
With the implementation of the PA process, drugs will
be considered "preferred" or "non-preferred". Non-preferred drugs will require PA as a condition for
payment by the program. The PDL is
established by selected therapeutic classes for those drugs that PA is not
required. Drugs in these
therapeutic classes that are not included on the PDL shall require PA and
prescribing practitioners must obtain PA by contacting the University of
Louisiana at Monroe (ULM), College of Pharmacy Prior Authorization Unit. Information on the process is included in the attached documents. Providers will be notified of drugs selected for placement on the PDL by
selected therapeutic classes prior to the effective dates.
Implementation
of the PA process will be by a phased-in approach starting with the Proton Pump
Inhibitors and the COX2 Inhibitors therapeutic classes on June 10, 2002.
The following material is attached to assist you in
the new process:
1. A listing of drugs in the first group of therapeutic classes to be
included in the PA process with effective implementation dates.
2. A process and procedures document, "Louisiana Medicaid Pharmacy
Benefits Management Prior Authorization Program".
Information on the Prior Authorization process,
including the PDL, is also available on the Louisiana Medicaid website (www.lamedicaid.com).
This website will be updated when changes (additions or deletions) are
made to the PDL. PDL changes will
also be in a message on the provider"s remittance advice.
Thank you for your cooperation as we implement this
new process. We appreciate your
participation in the Medicaid program
Sincerely,
Ben A. Bearden
Director
BAB/mjt
Attachments (3)
The above letter and the Preferred Drug
List are
also available in PDF format on the Downloadable
Forms and Files page.